Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus

Table 2 Factors contributing to sustained virological response in the per protocol analysis

	Univariate			Multivariate
	Odds ratio	95%CI	P value	Odds ratio	95%CI	P value
Age, ≥ 70 yr	2.61	0.70, 9.82	0.1494
Sex, male	4.76	0.85, 88.89	0.0781
History of IFN-based therapy	5.12	1.39, 20.98	0.0147a	7.05	1.65, 36.08	0.0084a
Liver cirrhosis	6.72	1.78, 32.29	0.0048a	2.13	0.31, 14.34	0.4315
FIB-4 index, > 3.25	2.11	0.58, 8.54	0.2546
History of HCC	8.87	2.36, 37.04	0.0015a	7.67	1.30, 60.30	0.0233a
IL28B-SNP, non TT	1.21	0.17, 5.55	0.8214
ITPA-SNP, non CC	0.45	0.02, 2.63	0.4177
HCV genotype, 2A	2.78	0.67, 18.84	0.1687
Viral load, ≥ 6 logIU/mL	1.53	0.41, 7.31	0.5478
RBV dose reduction	2.29	0.47, 8.89	0.2757
Rapid virological response	0.86	0.22, 4.15	0.8401

^aP < 0.05, significant difference. IFN: Interferon; FIB: Fibrosis; HCC: Hepatocellular carcinoma; IL28B: Interleukin-28B; SNP: Single nucleotide polymorphisms; ITPA: Inosine triphosphate pyrophosphatase; HCV: Hepatitis C virus; RBV: Ribavirin.